AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by ECMO-VA for Refractory Cardiogenic Shock

Recruitingn/aAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
💬

In plain words

What the trial is, and whether it could suit you

Brief Summary : Rhythm disorders are a frequent and potentially serious complication of critical patients in the ICU and postoperative cardiac surgery. In particular, atrial fibrillation (AF) is the most common rhythm disorder in patients admitted to the ICU and is associated with excess mortality during acute circulatory failure. In postoperative cardiac surgery, AF affects 15 to 45% of patients. In addition to hemodynamic effects, AF increases the risk of stroke, bleeding, respiratory or renal failure, and doubles mortality at 30 days and 6 months. In the longer term, the recurrence rate of AF within 1 year after hospital discharge is about 50%. Similarly, other rhythm disorders, supraventricular or ventricular, can be life-threatening in ICU patients. While the incidence and complications of rhythm disorders are well documented during sepsis, cardiogenic shock or after cardiac surger

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patient 18 years of age or older * Assistance with VA ECMO Exclusion Criteria: * Opposition to the use of data. * Persons under legal protection (curators, guardianship), judicially safeguarded. * VA ECMO for refractory cardiac arrest.
💊

What it tests

  • Follow up by phone call
📍

Where

20 sites
CHU Angers
Angers, France
Hospices Civils de Lyon - Hôpital Louis Pradel
Bron, France
CHU Caen Normandie - Hôpital Côte de Nacre
Caen, France
CHRU Tours - Hôpital Trousseau
Chambray-lès-Tours, France
CHU Dijon Bourgogne - Hôpital François Mitterrand
Dijon, France
CHU Grenoble Alpes - Site Nord
Grenoble, France
CHU Lille - Institut Cœur Poumon
Lille, France
CHU Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France

…and 12 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy